Log in to save to my catalogue

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: c...

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: c...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b40b7ac28a984159b4bb8b27ecd44658

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

About this item

Full title

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Publisher

England: BioMed Central Ltd

Journal title

Journal of hematology and oncology, 2016-04, Vol.9 (39), p.39-16, Article 39

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20-30 % bone marrow blasts (AML20-30, formerly MDS-RAEB-t) to be categorised and treated as either MDS or AML. In addition, an artificial distinction between AML20-30 and AML30+ was made by regulatory agencies by initially restricting...

Alternative Titles

Full title

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_b40b7ac28a984159b4bb8b27ecd44658

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b40b7ac28a984159b4bb8b27ecd44658

Other Identifiers

ISSN

1756-8722

E-ISSN

1756-8722

DOI

10.1186/s13045-016-0263-4

How to access this item